- Chardan has initiated coverage of Immuneering Corp (NASDAQ:IMRX) with a Buy rating and a price target of $18.
- Immuneering’s lead candidate, IMM-1-104, an oral MEK inhibitor, is on track for 3Q22 IND filing, with potential for data 12-18 months later.
- Chardan summarized the drivers as follows:
- IMM-1-104’s CRAF bypass prevention mechanism and ~2-hour half-life differentiate it from approved and clinical-stage MEK inhibitors.
- Initial focus on biomarker-defined populations with high unmet need increase the chances of seeing a clear activity signal and favorable benefit/risk profile.
- If Immuneering’s “deep cyclic inhibition” strategy does translate to better tolerability, IMM-1-104 could be attractive as a backbone in combination regimens targeting other MAPK nodes or parallel pathways.
- Proof-of-concept for IMM-1-104 and the translational bioinformatics platform could attract partnership interest for other pipeline programs.
- Price Action: IMRX shares are up 11.30% at $6.29 during the market session on the last check Friday.
Edward Snowden Reacts To New Report On COVID-19 Lab-Leak Theory: ‘Corporations Must Never Again Be Permitted To Police Speech’
Edward Snowden decried “institutional” and “social media corpo” response back in the first half of 2020 regarding the origins of COVID-19 as reports emerged that U.S.
